Current management of inflammatory bowel disease and colorectal cancer

Gastrointestinal Cancer Research

Volumn 4, Issue 2, 2011, Pages 53-61

  Mattar, Mark C ^a,b   Lough, Denver ^c   Pishvaian, Michael J ^c   Charabaty, Aline ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; COLON; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENTERITIS; GASTROINTESTINAL DYSPLASIA; HIGH RISK POPULATION; HUMAN; MORTALITY; PRIMARY SCLEROSING CHOLANGITIS; RECTUM; REVIEW; RISK FACTOR; SIGMOID; TUMOR LOCALIZATION; ULCERATIVE COLITIS;

EID: 80053032817     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Calkins BM, Lilienfeld AM, Garland CF, et al: Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci 29(10):913-920, 1984
2. Loftus EV Jr: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 6(6):506-513, 2004
3. Crohn BB: The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Amer J Med Sci 170:220-228, 1925
4. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(suppl 2):1-5, 2003
5. Lennard-Jones JE, Ritchie JK, Williams CB: Cancer surveillance in ulcerative colitis: experience over 15 years. Lancet 2:149-152, 1983
6. Munkholm P, Loftus EV Jr, Reinacher-Schick A, et al: Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 73(1):11-19, 2006
7. Richards ME, Rickert RR, Nance FC: Crohn's disease-associated carcinoma: a poorly recognized complication of inflammatory bowel disease. Ann Surg 209(6):764-773, 1989
8. Gyde S, Dew NJ: Mortality in ulcerative colitis. Gastroenterology 83:36-43, 1982
9. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut 48(4):526-535, 2001
10. Levin B: Inflammatory bowel disease and colon cancer. Cancer 70(5 suppl):1313-1316, 1992
11. Choi PM, Zelig MP: Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35(7):950-954, 1994
12. Gillen CD, Walmsley RS, Prior P, et al: Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35(11):1590-1592, 1994
13. Lakatos PL, Lakatos L: Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14(25):3937-3947, 2008
14. Zisman TL, Rubin DT: Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol 14(17):2662-2669, 2008
15. Velayos FS, Loftus EV Jr, Jess T, et al: Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 130(7):1941-1949, 2006
16. Askling J, Dickman PW, Karlén P, et al: Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357(9252):262-266, 2001
17. Rutter MD, Saunders BP, Wilkinson KH, et al: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53(12):1813-1816, 2004
18. Smith MP, Loe RJ: Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 110:239-246, 1965
19. Lakatos L, Mester G, Erdelyi Z, et al: Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 12(3):205-211, 2006
20. Loftus EV Jr, Harewood GC, Loftus CG, et al: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54(1):91-96, 2005
21. Shetty K, Rybicki L, Brzezinski A, et al: The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94(6):1643-1649, 1999
22. Kornfeld D, Ekbom A, Ihre T: Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41(4):522-525, 1997
23. Ekbom A, Helmick C, Zack M, et al: Ulcerative colitis and colorectal cancer: a populationbased study. N Engl J Med 323(18):1228-1233, 1990
24. Xie J, Itzkowitz SH: Cancer in inflammatory bowel disease. World J Gastroenterol 14(3):378-389, 2008
25. Feagins LA, Souza RF, Spechler SJ: Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6(5):297-305, 2009
26. Rutter M, Saunders B, Wilkinson K, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2):451-459, 2004
27. Murthy S, Flanigan A, Clearfield H: Colorectal cancer in inflammatory bowel disease: molecular and clinical features. Gastroenterol Clin N Am 31(2):551-564, 2002
28. Kawanishi S, Hiraku Y, Pinlaor S, et al: Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387(4):365-372, 2006
29. Liao J, Seril DN, Lu GG, et al: Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice. Mol Carcinog 47(8):638-646, 2008
30. Crivello A, Giacalone A, Vaglica M, et al: Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci 1089:98-103, 2006
31. van Dieren JM, Wink JC, Vissers KJ, et al: Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol 15(4):216-222, 2006
32. Willenbucher RF, Aust DE, Chang CG, et al: Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154(6):1825-1830, 1999
33. Tahara T, Inoue N, Hisamatsu T, et al: Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol 20(5):710-715, 2005
34. Itzkowitz S: Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol 36(5 suppl):S70-74; discussion S94-96, 2003
35. Gavert N, Ben-Ze'ev A: beta-Catenin signaling in biological control and cancer. J Cell Biochem 102(4):820-828, 2007
36. Hill KA, Wang KL, Stryker SJ, et al: Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer. Oncol Rep 11(5):951-956, 2004
37. Bernstein CN: Neoplastic and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2(6):451-459, 2000
38. Itzkowitz SH, Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126(6):1634-1648, 2004
39. Bernstein CN, Shanahan F, Weinstein WM: Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343(8889):71-74, 1994
40. Itzkowitz SH, Present DH: Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11(3):314-321, 2005
41. Biancone L, Travis S, Escher JC, et al: European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohn Colitis 2:63-92, 2008
42. Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51(suppl 5):V10-12, 2002
43. Hanauer SB, Meyers S: Management of Crohn's disease in adults. Am J Gastroenterol 92(4):559-566, 1997
44. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99(7):1371-1385, 2004
45. Rubin CE, Haggitt RC, Burmer GC, et al: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103(5):1611-1620, 1992
46. Elmunzer BJ, Higgins PD, Kwon YM, et al: Jumbo forceps are superior to standard largecapacity forceps in obtaining diagnostically adequate inflammatory bowel disease surveillance biopsy specimens. Gastrointest Endosc 68(2):273-278; quiz 334-336, 2008
47. Mitooka H, Fujimori T, Ohno S, et al: Chromoscopy of the colon using indigo carmine dye with electrolyte lavage solution. Gastrointest Endosc 38(3):373-374, 1992
48. Kiesslich R, Hoffman A, Neurath, MF: Colonoscopy, tumors, and inflammatory bowel disease: new diagnostic methods. Endoscopy 38(1):5-10, 2006
49. Hurlstone DP, Sanders DS, Lobo AJ, et al: Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 37(12):1186-1192, 2005
50. Rubin DT, Rothe JA, Hetzel JT, et al: Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65(7):998-1004, 2007
51. Kiesslich R, Goetz M, Lammersdorf K, et al: Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132(3):874-882, 2007
52. Hurlstone DP, Kiesslich R, Thomson M, et al: Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis. Gut 57(2):196-204, 2008
53. Dekker E, van den Broek FJ, Reitsma JB, et al: Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 39(3):216-221, 2007
54. Bantel H, Berg C, Vieth M, et al: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95(12):3452-3457, 2000
55. Wahl C, Liptay S, Adler G, et al: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101(5):1163-1174, 1998
56. Kaiser GC, Yan F, Polk DB: Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 116(3):602-609, 1999
57. Reinacher-Schick A, Seidensticker F, Petrasch S, et al: Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32(3):245-254, 2000
58. Reinacher-Schick A, Schoeneck A, Graeven U, et al: Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24(3):443-451, 2003
59. Velayos FS, Terdiman JP, Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100(6):1345-1353, 2005
60. Terdiman JP, Steinbuch M, Blumentals WA, et al: 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 13(4):367-371, 2007
61. Pinczowski D, Ekbom A, Baron J, et al: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107(1):117-120, 1994
62. Eaden J, Abrams K, Ekbom A, et al: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14(2):145-153, 2000
63. Tung BY, Emond MJ, Haggitt RC, et al: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134(2):89-95, 2001
64. Pardi DS, Loftus EV Jr, Kremers WK, et al: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124(4):889-893, 2003
65. Sjoqvist U, Tribukait B, Ost A, et al: Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 24(5B):3121-3127, 2004
66. Winther KV, Langholz E, Munkholm P, et al: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2:1088-1095, 2004
67. Odze RD, Farraye FA, Hecht JL, et al: Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2(7):534-541, 2004
68. Ullman T, Croog V, Harpaz N, et al: Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125(5):1311-1319, 2003
69. Befrits R, Ljung T, Jaramillo E, et al: Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 45(5):615-620, 2002
70. Connell WR, Lennard-Jones JE, Williams CB, et al: Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107(4):934-944, 1994
71. Ullman TA, Loftus EV Jr, Kakar S, et al: The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 97(4):922-927, 2002
72. Lim CH, Dixon MF, Vail A, et al: Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 52(8):1127-1132, 2003